Alpine Immune Sciences Inc (NASDAQ:ALPN) has been assigned a consensus rating of “Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.75.
ALPN has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.
In related news, VP James Paul Rickey bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average price of $4.95 per share, for a total transaction of $49,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 75.10% of the company’s stock.
A hedge fund recently bought a new stake in Alpine Immune Sciences stock. Leonard Rickey Investment Advisors P.L.L.C. bought a new position in shares of Alpine Immune Sciences Inc (NASDAQ:ALPN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $42,000. Leonard Rickey Investment Advisors P.L.L.C. owned about 0.05% of Alpine Immune Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 47.04% of the company’s stock.
Shares of ALPN traded up $0.01 during mid-day trading on Monday, reaching $4.21. The stock had a trading volume of 9,852 shares, compared to its average volume of 12,707. The firm has a market capitalization of $78.55 million, a price-to-earnings ratio of -1.57 and a beta of 1.89. Alpine Immune Sciences has a 12 month low of $3.66 and a 12 month high of $8.59. The business’s fifty day moving average price is $4.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.33 and a current ratio of 7.33.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01). As a group, equities analysts anticipate that Alpine Immune Sciences will post -2.67 earnings per share for the current fiscal year.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Story: Overbought
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.